A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer

Monter Cancer Center, Lake Success

Charité Campus Virchow-Klinikum, Berlin

Thomas Jefferson University, Philadelphia

Medical University of South Carolina, Charleston

Florida Cancer Specialists and Research Institute, St. Petersburg

Florida Cancer Specialists, Fort Myers

Sarah Cannon Research Institute SCRI, Nashville

Tennessee Oncology PLLC, Nashville

Chattanooga Oncology Hematology Associates, Chattanooga

Fort Wayne Oncology & Hematology, Fort Wayne

Sanford Research/USD, Sioux Falls

Cancer Center of Kansas, Wichita

Nebraska Methodist Hospital, Omaha

Highlands Oncology Group, Fayetteville

Univ of Texas Health Science Center at San Antonio, San Antonio

University of Utah School of Medicine, Salt Lake City

TGen Clinical Research Services at Scottsdale Healthcare, Scottsdale

University of Arizona Cancer Center, Tucson

Comprehensive Cancer Centers of Nevada, Las Vegas

TRIO - Translational Research in Oncology-US, Inc., Los Angeles

UCLA Medical Center, Los Angeles

St Jude Medical Center, Fullerton

Cancer Center of Santa Barbara with Sansum Clinic, Santa Barbara

Comprehensive Blood and Cancer Center, Bakersfield

Central Coast Medical Oncology Corporation, Santa Maria

Smilow Cancer Hospital at Yale-New Haven, New Haven

H Lee Moffitt Cancer Center, Tampa

Dartmouth Hitchcock Medical Center, Lebanon

Rutgers Cancer Institute of New Jersey, New Brunswick

Roswell Park Cancer Institute, Buffalo

UPMC Hillman Cancer Center, Pittsburgh

Vanderbilt University Medical Center, Nashville

University of Wisconsin-Madison Hospital and Health Clinic, Madison

Hospital Universitari Vall d'Hebron, Barcelona